EUVIMEDEUVIMED entdecken
Crossref

IKCS2021 Top Abstracts

Robert Figlin

Kidney Cancer Journal · 2021

DOI: 10.52733/kcj19n4-abs ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney Cancer Journal, 2021. Verfasst von Robert Figlin.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patient and Methods: Eligible patients with primary tumor and metastases are treated with one of the FDA approved ICI based combinations: ipililumab and nivolumab, axitinib and pembrolizumab, or axitinib and avelumab.Cabozantinib + nivolumab and lenvatinib + pembrolizumab combinations are being added into the next amendment.Urology evaluation and response assessment is required.Randomization occurs between 10-14 weeks of therapy; 1:1 to receive CN followed by systemic therapy or to continue on systemic therapy.statistical design & endPoints: The primary endpoint is overall survival.We estimate the median survival from time of randomization for the non-surgical arm will be 25 months.The study hypothesis is that CN will result in improvement in OS outcomes in advanced synchronous RCC post-initial systemic immune checkpoint-based combination therapy.With a sample size of 302 eligible, randomized participants (151 per arm) and a one-sided alpha=0.025, the study has 85% power to detect a 47% improvement in median survival (HR=0.68;1/0.68 = 1.47)Funding:NIH/NCI/NCTN grants U10CA180888, U10CA180819, U10CA180820 TIP09-89Zr-TLX250 for PET/CT imaging of clear cell kidney cancer Shuch B, Hayward C, Pantuck A trial design: Zircon is an open label, phase 3 study evaluating the performance of Zirconium-89-labeled girentuximab (89Zr-TLX250) for detecting ccRCC.The trial is open at 34 international sites (NCT03849118).The primary endpoint is the sensitivity/specificity of PET/CT imaging with 89Zr-TLX250 to non-invasively predict resection histology.Secondary endpoints include safety/tolerability, performance in cT1a, positive/ negative predictive value, and inter/intra-observer variability.Key inclusion criterion includes a solitary, localized, cT1 lesion scheduled for resection.Exclusion criterion include planned biopsy and concurrent malignancy requiring treatment

Zitieren

APA

Figlin, R. (2021). IKCS2021 Top Abstracts. Kidney Cancer Journal. https://doi.org/10.52733/kcj19n4-abs

Vancouver

Figlin R. IKCS2021 Top Abstracts. Kidney Cancer Journal. 2021. doi:10.52733/kcj19n4-abs

BibTeX
@article{Figlin2021,
  author = {Figlin, Robert},
  title = {IKCS2021 Top Abstracts},
  journal = {Kidney Cancer Journal},
  year = {2021},
  doi = {10.52733/kcj19n4-abs}
}
Kostenlos starten →